Tag Archives: IBB

Top Warren Buffett Stocks To Buy For 2018

Sometimes identifying the best stocks to buy can be difficult, but you could do a lot worse than check out the stocks selected by one of the world’s wealthiest hedge fund managers — George Soros.

Self-made Soros fled Hungary and funded his way through an economics degree by working as a railway porter and waiter. Years of successful investing gave him a net worth of $25.2 billion and the no. 1 ranking on Forbes’ hedge fund manager rich list. (Warren Buffett, who has a whopping $75 billion net worth, wins the no.1 title for the wider finance and investments community). In 1992, Soros shorted the British pound and reportedly made a profit of $1 billion. He became known as the man who broke the Bank of England.

Now we can track the latest trades of his family office, Soros Fund Management. Just-released SEC forms reveal a valuable glimpse into which stocks Soros likes, and which he doesn’t. I looked back over 2017 and pinpointed Soros’ best stock picks this year. These are the stocks that this legendary hedge fund manager is most bullish on. Note that Soros has just shifted an incredible $18 billion from the fund to charity. Following the move, the fund manages about $4 billion in portfolio assets.

Top Warren Buffett Stocks To Buy For 2018: Orchid Island Capital, Inc.(ORC)

Advisors’ Opinion:

  • [By Paul Ausick]

    Orchid Island Capital Inc. (NYSE: ORC) fell about 9.7% to post a new 52-week low of $7.85 Thursday after closing at $8.69 on Wednesday. The 52-week high is $12.60. Volume of about 5.2 million was nearly 5 times the daily average of around 1.1 million. The company lowered its monthly dividend by 3 cents last night.

Top Warren Buffett Stocks To Buy For 2018: The Rubicon Project, Inc.(RUBI)

Advisors’ Opinion:

  • [By Paul Ausick]

    The Rubicon Project Inc. (NYSE: RUBI) dropped about 2.4% on Tuesday to post a new 52-week low of $8.64 against a 52-week high of $20.37. Volume of around 680,000 million was about 15% below the daily average of around 780,000. The stock closed at $8.85 on Monday night. The ad marketplace has formed a strategic alliance with Flipboard that will allow advertisers to buy ad space on Flipboard.

  • [By Paul Ausick]

    Rubicon Project Inc. (NYSE: RUBI) dropped about 1.9% Friday, to post a new 52-week low of $5.65 after closing at $5.76 on Thursday. The stock’s 52-week high is $20.37. Volume was nearly 4 times the daily average of around 740,000 shares. The company had no specific news.

  • [By Paul Ausick]

    Rubicon Project Inc. (NYSE: RUBI) dropped about 29% Wednesday to post a new 52-week low of $5.96 after closing Tuesday at $8.39. Volume of more than 6.1 million shares was more than 10 times the daily average of less than 600,000. The company named a new CEO and reported weak results after markets closed Tuesday.

Top Warren Buffett Stocks To Buy For 2018: NO Name(ACI)

Advisors’ Opinion:

  • [By Robert Weinstein]

    Lawsuit after lawsuit, a billion dollars in cost overruns, taxpayer subsidies and the most expensive coal plant to operate causing electric rates to skyrocket, if this becomes the norm. The new project is called Plant Ratcliffe by Southern Co.
    Plant Ratcliffe is quite the boondoggle, but proponents say it always costs more to build the first one and costs will come down as the technology improves. More plants are in the planning stages and may bring a needed shot in the arm to mining stocks.
    Alpha Natural Resources (ANR), Walter Energy (WLT), Arch Coal (ACI), Cliffs Natural Resources (CLF), Peabody Energy (BTU), and James River Coal (JRCC) are companies that may benefit from increased demand for coal.
    Not all coal or coal companies are equal, so it’s crucial to discriminate based on your investment time-horizon goals. With that said, the announcement should have been followed by a deep sell-off in coal and utility related stocks. But something happened.
    Or, rather, didn’t happen.
    The above coal stocks didn’t sell off tremendously and are largely moving along with the rest of the market today. This is noteworthy because stocks don’t bottom on good news, they reach a bottom on awful news. Let me explain: When a stock chart continues trending lower, what you’re witnessing is investors throwing in the towel and moving on.
    Leaving aside bankruptcies for a moment, almost all stocks have a core group of investors that are commonly known as the “strong hands.” A stock is at the bottom when the weak hands are gone. At some point, distressing news (like an unfavorable EPA announcement regarding coal) hits the wire and the related stock or stocks react with little or no movement. This is what we are witnessing right now in coal-related companies.

Top Warren Buffett Stocks To Buy For 2018: V.F. Corporation(VFC)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Today, the Wall Street Journal reported that Kate Spade & Co is considering a sale of the company, following pressure from activist investors given the volatile performance ever since Kate Spade became a mono brand company over 2 years ago. The article cites thatKate Spade has hired an investment bank and has reached out to possible buyers (including other retailers) althoughKate Spade has not responded. This comes at a time when brand houses like VF Corp. (VFC), PVH Corp. (PVH), Hanesbrands (HBI), Michael Kors Holdings (KORS), and Coach have said they are looking to make a branded acquisition, andKate Spade could be one of the strongest candidates. While other brands are seeing negative comps, pulling back on wholesale exposure or restructuring,Kate Spade continues to grow.

  • [By Leo Sun]

    VF Corp. (NYSE:VFC) owns a massive portfolio of apparel companies, including The North Face, Timberland, Wrangler, Lee, and Vans. It’s raised its dividend annually for over four decades — making it an elite “dividend aristocrat” which has boosted its payout for at least 25 straight years. VF currently pays a forward yield of 3.1%, which is supported by a payout ratio of 55%. The stock trades at 21 times earnings.

  • [By Jeremy Bowman]

    The North Face, in particular, seems like a cautionary tale. The outdoor gear and apparel maker had its IPO in 1996. By 1999 sales were falling and the company put up a $100 million loss. In 2000,VF Corporation(NYSE:VFC) acquired it for just $25.4 million, despite $238 million in sales and a once-popular brand. Today, under the guidance of VF Corp, The North Face now has more than $2 billion in annual sales.

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11

Top Warren Buffett Stocks To Buy For 2018: iShares Nasdaq Biotechnology Index Fund(IBB)

Advisors’ Opinion:

  • [By Craig Jones]

    Guy Adami believes that iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) is a Buy. He explained that it held well in a tough trading session for the rest of the market.

  • [By ]

    The SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels back in mid-November.

  • [By Ben Levisohn]

    Endo International slumped 8.6% to $14.00 today, while the S&P 500 rose 0.3% to 2,275.32. The iShares Nasdaq Biotechnology (IBB) fell 3% to $277.94, while the SPDR S&P Pharmaceuticals ETF (XPH) dropped 2.9% to $39.41.

  • [By Ben Levisohn]

    Shares of Amgen have dropped 0.8% to $146.61 at 2:44 p.m. today, while Regeneron Pharmaceutical has fallen 0.5% to $369.83, and Celgene has gained 2% to $118.10. The iShares Nasdaq Biotechnology ETF (IBB) has risen 0.4% to $269.86.

stock market today news

Bob Doll Explains How Stocks Could Be Derailed

Mercer Bullard: Think DOLs Fiduciary Rule Is Too Strict? Blame SEC

Gundlach Sounds Fed Alarm, Warns of Selloff Near Inauguration Day

This week, the U.S. Chamber of Commerce added to the welter of speculation over the Department of Labor’s fiduciary rule’s fate.

Chamber CEO Thomas Donohue said the organization is urging the incoming Trump administration’s transition team to undo the regulation. To date, the Trump administration hasn’t communicated its position on the rule.

Some firms have begun to release those changes along with education initiatives for advisors. Others have kept compliance efforts close to the vest for competitive purposes, said Larson.

But all will have to start releasing their intended course of action, and soon, in order to avoid the litigation and competition risks that will come from not being prepared for implementation.

Melissa Dimitri, a senior manager in Grant Thornton’s Advisory Services, which provides strategic consulting to financial services and insurance companies, says her team is not swayed by the back-and-forth speculation over the rule’s fate.

stock market today news: China Advanced Construction Materials Group, Inc.(CADC)

Advisors’ Opinion:

  • [By Lisa Levin]

    China Advanced Constructn Mtrls Grp Inc (NASDAQ: CADC) shares shot up 225 percent to $7.15 after gaining 2.33 percent on Wednesday.

    Shares of Smart Global Holdings Inc (NASDAQ: SGH) got a boost, shooting up 29 percent to $36.98 after the company issued strong guidance. The company updated Q1 guidance, raising adjusted EPS from 79 cents-83 cents to 90 cents-93 cents. Sales guidance was raised from $225 million-$240 million to $250 million-$260 million.

stock market today news: Graham Corporation(GHM)

Advisors’ Opinion:

  • [By Monica Gerson]

    Graham Corporation (NYSE: GHM) is expected to report its quarterly earnings at $0.12 per share on revenue of $23.54 million.

    Heico Corp (NYSE: HEI) is estimated to post its quarterly earnings at $0.54 per share.

stock market today news: Toll Brothers Inc.(TOL)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The stock market once again proved its resiliency on Wednesday, bouncing back from extensive declines early in the session to recover most of its losses. The Dow Jones Industrials actually managed to post yet another record close with a modest gain, and although other major market benchmarks suffered declines, they weren’t significant. Moreover, some favorable news from certain pockets of the market helped bolster investor confidence. Toll Brothers (NYSE:TOL), Lantheus Holdings (NASDAQ:LNTH), and Norwegian Cruise Line Holdings (NASDAQ:NCLH) were among the top performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

  • [By Jim Powell]

    Steve Halpern: You mentioned home builders and one that you’ve been bullish on is Toll Brothers (TOL). Do you still like that stock?

    Jim Powell: I certainly do. It’s in there for the long haul. They’ve made some really good strategic decisions. One of the trends that I’ve been following is the millennial generation and what their habits are and what their preferences are.

  • [By Lisa Levin]

    Toll Brothers Inc (NYSE: TOL) reported stronger-than-expected profit for its third quarter, while revenue missed estimates

    Toll Brothers posted quarterly earnings of $0.87 per share on revenue of $1.502 billion. However, analysts were expecting earnings of $0.69 per share on revenue of $1.51 billion.

  • [By WWW.THESTREET.COM]

    Next, on Tuesday, earnings from Darden Restaurants (DRI) and KB Home (KBH) . Cramer said he liked both companies, but prefers Toll Brothers (TOL) among the homebuilders.

  • [By Lisa Levin]

    Toll Brothers, Inc. (NYSE: TOL) reported downbeat results for its fourth quarter.

    Toll Brothers posted quarterly earnings of $1.17 per share on revenue of $2.03 billion. However, analysts expected earnings of $1.19 per share on revenue of $2.08 billion.

  • [By Eileen Rojas]

    Toll Brothers has rising sales volume and unit prices
    For the third quarter ended on July 31, Toll Brothers’ (NYSE: TOL  ) net income was $46.6 million, or $0.26 per share. The latest income figures were down 24% from last year’s third-quarter results of $61.6 million, or $0.36 per share. The company’s total quarterly revenues were $689.2 million, up 24% over last year, and homebuilding deliveries were 1,059 units, up 10% compared to the same period last year.

stock market today news: Mitsubishi UFJ Financial Group Inc(MTU)

Advisors’ Opinion:

  • [By Jim Jubak, Senior Markets Editor, MoneyShow.com]

    The one currency that is running against the weak dollar tide is the Japanese yen. The yen initially climbed on the Fed’s no taper decision—rising to 97.75 on the news—but then fell all the way back to 99 yen to the dollar and finished yesterday at 99.42. (Remember that since the yen is quoted in yen to the dollar, a higher number is a sign of a weak yen and a smaller number means the yen is getting stronger.) The thinking seems to be that the recent Japanese trade deficit will push the Bank of Japan to further weaken the yen, in order to boost Japanese exports. I continue to think that the yen will finish 2013 at weaker levels than current trading, and that leads me to continue to hold positions in Japanese stocks such as Toyota Motor (TM) and Mitsubishi UFJ Financial Group (MTU). Both stocks are members of my Jubaks Picks portfolio.

stock market today news: iShares Nasdaq Biotechnology Index Fund(IBB)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Of course, Donald Trump took on the health care industry in his press conference today, so Gilead’s shares–and just about every other biotech and pharmaceutical company–are getting smacked down. Its stock fallen 2.4% to $25.03 at 3:30 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has fallen 2.9% to$278.49.

  • [By Ben Levisohn]

    Biotech stocks have been particularly unloved during the past year, with the iShares Nasdaq Biotech Index ETF (IBB) gaining just 7% to the S&P 500′s 20% rise. Today, however, Amgen (AMGN) is getting a lot of love from the market after releasing Street beating earnings and reporting that its anti-cholesterol drug reduced heart attacks.

  • [By WWW.THESTREET.COM]

    Biotechnology stocks had an incredible run between 2012 and 2015, and the iShares Nasdaq Biotechnology ETF (IBB) was up 395% in that time. After making the record high, however, the space came under pressure and the fund dropped below its 40-week moving average, eventually retracing 50% of its historic rally before finding support in the $240.00 area. Since that time, it has been moving in a horizontal channel below the 38% retracement level of the pullback range in the $300.00 area, and 2016 triple-bottom support.

  • [By ]

    The SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels back in mid-November.

  • [By Kumar Abhishek]

    It has not been a good year for Gilead Sciences (NSDQ:GILD) shareholders. Gilead stock is down bymore than 25% YTD and almost 30% in last one year. The stock has not only heavily underperformed the broader marketbut has also lagged the sector index iShares NASDAQ Biotech Index ETF (NSDQ:IBB) which is down nearly 17% YTD.The poor performance of the stock is mainly caused by declining HCV sales numbers. HCV was the main growth driver for Gilead till a few quarters back. But the sales in this segment have seen aconsistent decline over the last few quarters which has lead to an increasingly bearish sentiment around the stock. Many analystsbelieve that the bearish sentiment is overdone, and the stock will rebound on strong fundamentals.

  • [By Ben Levisohn]

    Shares of Gilead Sciences have dipped 0.1% to $68.97 at 1:05 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has risen 0.4% to $296.51.

[3 Cant-Miss Charts] More Holiday Gains Are Here!

Traders have devoured almost every single dip so far this year.

The markets big winners have enjoyed an amazing rally in 2017. But many of these popular stocks look like they need more rest before attempting to fight back toward their highs.

Thats why market rotation has been one of our big trading themes this month. If you want to continue banking short-term gains, its time to reevaluate your positions and jump on the most lucrative trends for the final two trading weeks of the year and beyond.

Luckily, our charts continue to offer plenty of clues as to what stocks and sectors will outperform in the weeks and months ahead.

To help you fight through the noise, were going to dive below the major averages to discover what trades could blast higher during the holiday season and which plays could run into more trouble.

Lets get started

1. Biotech Gets Volatile

The SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels back in mid-November.

Their recent performance had been less than impressive. The small-cap SPDR S&P Biotech ETF dropped almost 8% below its early October highs. Meanwhile, the iShares Nasdaq Biotechnology ETF fell almost 9% over the same timeframe.

We were hoping for a meaningful bounce from our favorite fast-moving biotech stocks. But instead, all the market gave us was a choppy mess.

Waiting for a Bounce

XBI has slowly lost ground since the small-cap biotech ETF topped out in early October. Its now more than 8% below its highs and becoming more volatile every day.

To be fair, were not totally writing off this group. These stocks probably just need some time to reset. On a positive note, the large-cap iShares Nasdaq Biotechnology ETF has managed to hold above its 200-day moving average. If these stocks can grab a little momentum here, we could see them return to form in 2018.

2. Semis Search for Support

Semiconductor stocks have been among 2017s strongest market leaders.

But that doesnt mean the sector is immune from market forces. The VanEck Vectors Semiconductor ETF (NYSE:SMH) endured a choppy consolidation period beginning in June that lasted more than three months. But by mid-September, this industry was setting up for a powerful breakout once again as market focus shifted back to the tech sector.

Now its cooling off once again

VanEck Vectors Semiconductor ETF

Semis are getting hit after posting a powerful two-month romp that topped out in late November. Whether we get a bounce like we witnessed back in the summer remains to be seen. Well keep our eyes peeled

3. Palladium Breaks Out

Palladium is ripping higher thanks to its industrial applications. Its used in catalytic converters in cars and trucks, as well as capacitors in consumer electronic equipment.

Most investors arent paying a lick of attention to palladium. But as we showed you last month, this forgotten precious metal is beating the pants off the major averages this year.

Now its breaking out to new highs again.

Palladium Finds New Highs

This is one of the cleanest charts on the market right now. You cant argue with this beautiful uptrend!

Our ETFS Physical Palladium Shares (NYSE:PALL) jumped higher by almost 2% yesterday. Thats just what it needed to begin a new push into 2018

Sincerely,

Greg Guenthner
forThe Daily Reckoning

penny stock forum

Related AMTD During A Bullish March, These Were The Stocks That Were Net Buys Among Retail Investors What Success Is Made Of: Investors, Execs And Entrepreneurs Talk Routines And Role Models
Related Investor Movement Index (IMX) for March 2017 Wall Street's M&A Chatter From March 30: Digital Ally, Rio Tinto-Alcoa, NextEra Elliott Management Activist Streak Continues With Demands at BHP Billiton (GuruFocus)

After a another month of record highs for the Dow Jones Industrial Average, which surpassed the $21,000 mark, and the S&P 500, which topped $2,400, TD Ameritrade Holding Corp. (NASDAQ: AMTD) released its March report for the Investor Movement Index. Tracking retail investor movement in and out of equities, the IMX, like the markets at large, hit a new high of 6.22 and showed retail investors were net buyers of equity over the month.

penny stock forum: Intuit Inc.(INTU)

Advisors’ Opinion:

  • [By Asit Sharma]

    It’s tax season — the four months when tax and small-business software providerIntuit Inc.(NASDAQ:INTU) makes most of its profit for the year. On Thursday, Intuit filed its fiscal second-quarter 2017 earnings report and issued a progress report on its tax business so far this year.Tax volumes are well off last year’s pace: Let’s review the details, as well as management’s interpretation, after a look at the headline numbers.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Intuit Inc. (NASDAQ: INTU) which jumped nearly 7% to $137.88. The stocks 52-week range is $101.81 to $140.25. Volume was 4.8 million on the day compared to the average of 1.9 million.

  • [By Shauna O’Brien]

    Morgan Stanley reported on Wednesday that it has downgraded financial management solution provider Intuit Inc. (INTU).

    The firm has cut its rating on INTU to “Underweight,” and has given the company a $62 price target. This price target suggests a 6% decline from the stock’s current price of $66.30. This downgrade reflects the company’s slowing growth of its tax business.

    Intuit shares were mostly flat during pre-market trading Wednesday. The stock is up 11% YTD.

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

penny stock forum: T-Mobile US, Inc.(TMUS)

Advisors’ Opinion:

  • [By Daniel Miller]

    As a rule of thumb, the two largest phone carriers in the U.S. have been dominant, followed by a smaller two in Sprint Corporation (NYSE:S) and T-Mobile (NASDAQ:TMUS). With a new administration that might view business deals differently than previous administrations, interest in a merger between Sprint and T-Mobile seems to be heating up. The idea is to create three ultra-competitive phone carriers rather than two dominant and two smaller carriers.

  • [By Chris Lange]

    T-Mobile US, Inc. (NASDAQ: TMUS) reported first quarter financial results after markets closed Monday. The company said that it had $0.80 in diluted GAAP earnings per share (EPS) and $9.61 billion in revenue, versus consensus estimates from Thomson Reuters that called for $0.34 in EPS and $9.62 billion in revenue. The same period from last year had $0.56 in EPS and $8.6 billion in revenue.

  • [By Brian Stoffel]

    But it was the powerhouse wireless division that probably accounted for most of the workforce growth. After all, AT&T is not the only wireless provider tapping the talent pool: Sprint (NYSE:S)made the 13th-most hires last year, and T-Mobile (NASDAQ:TMUS) came in at No. 21.

  • [By WWW.THESTREET.COM]

    Donald Trump’s election has proved a boon for shareholders of Sprint (S) , on the premise that a Republican administration would be open to a merger of the carrier to T-Mobile USA (TMUS) . Regulators under Obama had pushed back against Sprint Chairman Masayoshi Son’s goal of combining the U.S.’s third- and fourth-largest carriers.

penny stock forum: iShares Nasdaq Biotechnology Index Fund(IBB)

Advisors’ Opinion:

  • [By Ben Levisohn]

    One reason for this is the market’s continued ability to leverage what’s working and treat laggards in isolation. Biotechs had led early this year. But as profiled Monday, the iShares Nasdaq Biotech ETF (IBB) had just gotten back to that key resistance line (near 280), which had stunted many similar oversold rallies last year. So, while the pullback isn’t surprising, it is discouraging, especially if it means the IBB could waste the chance of leveraging the longer term bottoming formation.

  • [By Kumar Abhishek]

    Shares of Foster City, California-based, biotech major, Gilead Sciences, Inc(NASDAQ:GILD) have been on a consistent decline in the last one year or so. After being one of the best performers in the biotech space since 2012, Gilead stock has lost more than 12% in last one year, while theNasdaq Composite (INDX:COMPX) has gained by more than 24% in the same period, resulting in a massive underperformance. Gilead stock has underperformedeven the iShares NASDAQ Biotech Index ETF (NASDAQ:IBB) which has returned more than 14% during the same period. Gilead stock has been making lower lows and lower highs going into the earnings, indicating a clear downtrend in the stock. The stock hit its 52 week low of $69.78 recently on January 24th, just days ahead of its Q4 earnings result. Gilead Sciences, Incis scheduled to report its Q4 2016 and FY 2016 earnings on 7th of February, after the market close.

  • [By ]

    After sneaking lower to begin the new trading week, the SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels.

  • [By Ben Levisohn]

    Shares of Gilead Sciences have dipped 0.1% to $68.97 at 1:05 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has risen 0.4% to $296.51.

  • [By Ben Levisohn]

    Shares of Amgen have dropped 0.8% to $146.61 at 2:44 p.m. today, while Regeneron Pharmaceutical has fallen 0.5% to $369.83, and Celgene has gained 2% to $118.10. The iShares Nasdaq Biotechnology ETF (IBB) has risen 0.4% to $269.86.

  • [By Ben Levisohn]

    Biotech stocks have been particularly unloved during the past year, with the iShares Nasdaq Biotech Index ETF (IBB) gaining just 7% to the S&P 500′s 20% rise. Today, however, Amgen (AMGN) is getting a lot of love from the market after releasing Street beating earnings and reporting that its anti-cholesterol drug reduced heart attacks.

penny stock forum: Nabors Industries Ltd.(NBR)

Advisors’ Opinion:

  • [By Craig Jones]

    On CNBC's "Fast Money Halftime Report", Jon Najarian spoke about Nabors Industries Ltd. (NYSE: NBR). He said that somebody bought 6,500 contracts of the July 11 calls for $0.50 in the first half of the session. The trade breaks even at $11.50 or 16.28 percent above the current market price. Jon Najarian has a long position in the name and he is planning to hold it for a month.

  • [By Ben Levisohn]

    Last night, Weatherford International (WFT) reported a smaller than expected loss and announcing an alliance with Nabors Industries (NBR)–and the news was celebrated by the market.

  • [By Craig Jones]

    Pete Najarian was watching Nabors Industries Ltd. (NYSE: NBR). He said that the stock has been trading in a range between $8 and $18 over the last 52 weeks and although it spiked 2.82 percent on Wednesday, it's still close to the lower end of the range. Anticipating a move higher, traders were buying the June 11 calls for $0.30. Around 6,000 contracts were bought in the first half of the session. The trade breaks even at $11.30 or 10.78 percent above the current market price. Pete Najarian decided to buy the calls and he is going to hold them for 4-5 weeks.

Hot Safest Stocks To Buy Right Now

Sunnyvale, California based AMD (NSDQ:AMD)recently clinched a deal to put its GPUs in Google’s cloud platforms. Coming after AMD’s Alibaba (NYSE:BABA)deal last month, this deal is a much bigger win, and could open the doors to many more deals in the cloud services space, which have eluded AMD so far. By virtue of its early lead, this space has been dominated by arch rival Nvidia. Both, Amazon’s AWS and Microsoft’s Azure reportedly use only Nvidia GPUs at the moment. However, that could potentially change following this deal, owing to a combination of factors. Here’s why this deal could potentially be followed by a slew of other deals over the coming months.

AMD Will Benefit From The Cloud Battle

The battle is heating up in the cloud services space, and whichever way that goes, AMD may emerge as one of the beneficiaries. On November 15th, Alphabet Inc’s (NSDQ:GOOGL)Google announcedthat starting from early 2017, it would offer GPUs made by AMD and NVIDIA (NSDQ:NVDA)toGoogle Compute Engine and Google Cloud Machine Learning users. The announcement is a big win for AMD for multiple reasons.

Hot Safest Stocks To Buy Right Now: Firsthand Technology Value Fund, Inc.(SVVC)

Advisors’ Opinion:

  • [By Hibah Yousuf]

    Similarly, Twitter is also the biggest holding in the Firsthand Technology Value Fund (SVVC). With just over 1 million shares of the social media platform, Twitter represents nearly 11% of the total portfolio as of mid-year. Shares of Firsthand Technology Value jumped more than 6% Friday.

Hot Safest Stocks To Buy Right Now: Chimerix, Inc.(CMRX)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    The lead product candidate from Chimerix (CMRX) is brincidofovir (CMX001), a nucleotide analog.

    The drug is in Phase III clinical trials for the prevention of cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant (HCT) recipients and in kidney transplant recipients, as well as to treat adenovirus infection in allogeneic HCT patients.

Hot Safest Stocks To Buy Right Now: iShares Nasdaq Biotechnology Index Fund(IBB)

Advisors’ Opinion:

  • [By Kumar Abhishek]

    It has not been a good year for Gilead Sciences (NSDQ:GILD) shareholders. Gilead stock is down bymore than 25% YTD and almost 30% in last one year. The stock has not only heavily underperformed the broader marketbut has also lagged the sector index iShares NASDAQ Biotech Index ETF (NSDQ:IBB) which is down nearly 17% YTD.The poor performance of the stock is mainly caused by declining HCV sales numbers. HCV was the main growth driver for Gilead till a few quarters back. But the sales in this segment have seen aconsistent decline over the last few quarters which has lead to an increasingly bearish sentiment around the stock. Many analystsbelieve that the bearish sentiment is overdone, and the stock will rebound on strong fundamentals.

  • [By Ben Levisohn]

    Of course, Donald Trump took on the health care industry in his press conference today, so Gilead’s shares–and just about every other biotech and pharmaceutical company–are getting smacked down. Its stock fallen 2.4% to $25.03 at 3:30 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has fallen 2.9% to$278.49.

  • [By Ben Levisohn]

    One reason for this is the market’s continued ability to leverage what’s working and treat laggards in isolation. Biotechs had led early this year. But as profiled Monday, the iShares Nasdaq Biotech ETF (IBB) had just gotten back to that key resistance line (near 280), which had stunted many similar oversold rallies last year. So, while the pullback isn’t surprising, it is discouraging, especially if it means the IBB could waste the chance of leveraging the longer term bottoming formation.